Wemos in de Telegraaf: subsidies have made Zolgensma and its high price possible

8/8/2019 - News

1.9 million Euro. It is expected that that will be the price of the medicine Zolgensma, manufactured by the pharmaceutical company Novartis. At the end of this month, the European Medicines Agency (EMA) will give approval for this medicine. The Dutch newspaper De Telegraaf recently interviewed our global health advocate Ella Weggen about how the current medicines policy in the Netherlands has made the ludicrously high price of 1.9 million Euro possible.

Read more in the article in De Telegraaf (Dutch).

Photo: Venus Veldhoen

 

 

 

Receive our newsletter

  • instagram
  • linkedin
  • youtube